Clinical Trials Logo

RAS Mutation clinical trials

View clinical trials related to RAS Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05340621 Active, not recruiting - Melanoma Clinical Trials

NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Start date: May 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.

NCT ID: NCT04194359 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer. A total of 25 patients are planned to be enrolled.